2021
DOI: 10.1080/15384047.2021.1881026
|View full text |Cite
|
Sign up to set email alerts
|

Selecting the optimal parameters for sonoporation of pancreatic cancer in a pre-clinical model

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 15 publications
(7 citation statements)
references
References 41 publications
0
7
0
Order By: Relevance
“…SonoVue ® and Sonazoid™ are expected to undergo inertial cavitation at peak-negative pressures above 0.4 MPa [40,41], whereas the acoustic pressures used in this study were approximately half that. The use of stable cavitation to induce sonoporation has been shown before [17,42,43]. At these low-acoustic energy levels, an ultrasound-induced temperature rise of 0.2 °C (i.e., the TIs) is expected as the worst-case scenario; hence, ultrasound-induced hyperthermia is not expected to be the root cause of the drug delivery.…”
Section: Study Limitations and Future Workmentioning
confidence: 99%
“…SonoVue ® and Sonazoid™ are expected to undergo inertial cavitation at peak-negative pressures above 0.4 MPa [40,41], whereas the acoustic pressures used in this study were approximately half that. The use of stable cavitation to induce sonoporation has been shown before [17,42,43]. At these low-acoustic energy levels, an ultrasound-induced temperature rise of 0.2 °C (i.e., the TIs) is expected as the worst-case scenario; hence, ultrasound-induced hyperthermia is not expected to be the root cause of the drug delivery.…”
Section: Study Limitations and Future Workmentioning
confidence: 99%
“…Using xenograft mouse models of PDAC, Schultz et al investigated PDAC sonoporation using all four worldwide clinically-approved UCA (Optison, Definity, Lumason/SonoVue, and Sonazoid (GE Healthcare)) and two ultrasound regimens (2.0 MHz 20 ms pulses at low and high acoustic powers for 10 minutes) to identify the ideal parameters to increase therapeutic efficacy. 96 Treatment with high power ultrasound (I SPTA = 200 mW cm À2 ) utilizing Sonazoid as the UCA most consistently caused an increase in permeabilization across different experiments and markers of permeability. The results from this and other pre-clinical studies indicate that UCA weaken endothelial cell junctions, increase fenestration sizes, and can generate minute resealing pores in cells, all of which can facilitate deeper penetration of chemotherapeutic agents into the PDAC tumor.…”
Section: Materials Advances Reviewmentioning
confidence: 99%
“…The results from this and other pre-clinical studies indicate that UCA weaken endothelial cell junctions, increase fenestration sizes, and can generate minute resealing pores in cells, all of which can facilitate deeper penetration of chemotherapeutic agents into the PDAC tumor. 48,49,96 A Phase I clinical trial aimed at augmenting standard-of-care chemotherapy efficacy led to significant improvement in 10 PDAC patients receiving sonoporation treatment compared to 63 historical controls. 97,98 The results included tumor regression in 50% of the patients and a significant increase in the number of treatments patients were able to undergo (8.3 AE 6.0 cycles in controls, 13.8 AE 5.6 cycles after sonoporation treatment; p = 0.008).…”
Section: Microbubble Cavitation-based Drug Deliverymentioning
confidence: 99%
“…Overall, the higher power US exposure and Sonazoid were the most consistently effective, and a larger phase II clinical trial is being pursued. 117 Kotopoulis showed that compared to chemotherapy alone, US and MBs along with chemotherapy could increase the number of treatment cycles, extending the quality of life in patients. 118 The safety and efficacy of US+MBs for increasing the malignant tumors' chemotherapeutic sensitivity in the digestive system were studied.…”
Section: Interaction Of Ultrasound Withmentioning
confidence: 99%
“…Four different US contrast agents (UCAs), Definity, SonoVue, Optison, or Sonazoid and low- or high-power US exposure (60 and 200 mW/cm 2 , respectively) were tested for enhancing therapeutic efficacy. Overall, the higher power US exposure and Sonazoid were the most consistently effective, and a larger phase II clinical trial is being pursued . Kotopoulis showed that compared to chemotherapy alone, US and MBs along with chemotherapy could increase the number of treatment cycles, extending the quality of life in patients …”
Section: Interaction Of Ultrasound With Biological Systems: Physical ...mentioning
confidence: 99%